Xeltis Secures €50M Financing to Advance Commercialization of aXess, a Regenerative Vascular Graft for Hemodialysis

Xeltis Announces Nearly EUR 50 Million in New Round of Financing. This Round of Financing IncludesEuropean Investment BankUp to €37.5 million provided by the European Commission's "Investment Plan for Europe" and €10 million contributed by existing investors (including EQT through its Economics Fund 2 and Invest-NL). The funds raised will be used to promote the commercialization of the aXess product, including expansion.Production scale, recruitment of personnel, and support the ongoing development of other pipelines under research within the company.

Investor Evaluation

"Xeltis is at the forefront of this field, directly contributing to improving treatment outcomes for dialysis and cardiovascular patients. Therefore, we are proud to support Xeltis with a 37.5 million euro venture debt facility, helping it transform groundbreaking scientific achievements into practical therapies across Europe. This collaboration demonstrates how targeted European innovation investments can accelerate medical advancements and strengthen Europe's leadership in the medical technology sector."

---Robert de Groot  European Investment BankVice President

Executive Evaluation

"We are deeply grateful for the continued support from the European Investment Bank and existing investors, and we are proud of the confidence they have shown in Xeltis at this critical juncture. The pivotal trial of aXess in the EU has yielded extraordinary data, and with this financing, we now have both validation and resources to move towards commercialization. We plan to expand our production facilities and hire key personnel to bring aXess to market, revolutionizing vascular access treatment for hemodialysis patients."

---Eliane Schutte  CEO of Xeltis

“European Investment Bankis an important partner of Xeltis. We sincerely thank them for their continuous support. The current development momentum is rapid,European Investment Bank"The commitment and continued support from existing investors have laid a solid foundation for Xeltis to firmly advance towards commercialization."

---Alexander Goemans  CFO of Xeltis

This round of financing closely follows XeltisRelease of Key Clinical Trial Data for ltis in the EU (see specifics ataXess: One-Year Patency Rate of Regenerative Artificial Blood Vessel is 100%). This studyEvaluation of the patency, safety, and performance of the dialysis artificial vessel aXess in end-stage renal disease patients requiring vascular access for initiation or maintenance of hemodialysis treatment has achieved outstanding results. The study successfully met its primary endpoint, demonstrating superior sustained patency rates and significant improvements across all key metrics compared to standard therapy, such as reduced infection rates and fewer interventions. The pivotal trial of aXess in the United States is also proceeding smoothly towards pre-market approval, with interim data expected to be released in 2026.

The funds will also be used to advance Xeltis' broader pipeline of transformative implants. These products are all developed based on the company's proprietary Endogenous Tissue Restoration (ETR) platform technology, which incorporates the Nobel Prize-winning PFAS-free polymer breakthrough. The company's second clinical product for coronary artery bypass grafting...Products Under DevelopmentXABG, has shown extremely positive 24-month follow-up results, with effects unprecedented in artificial bypass surgery catheters. Xeltis in otherThe R&D pipeline for indications has also made significant progress.

These three products are all manufactured usingXeltisUnique Endogenous Tissue Restoration (ETR) Principle. So-calledETR Principle, that is, through the patient's natural healing systemDevelopmentThroughout ChinaImplantof the human bodyTissue, thereby forming new, natural, fully functionalBlood vessels or heart valves.As time goes by，ImplantGradually absorbed by the human bodyAbsorption.

XABG

XABGIt is a restorative artificial blood vessel used for coronary artery bypass surgery, prepared through synthesis and electrospinning, and can be made from the patient's own tissue.

Xeltis PVPrepared by electrospinning technology, thus it has a densePorous microstructure, it is precisely because of thesePorous MicrostructureExistence, which enables the patient's own tissue to quickly fill thesePorous MicrostructureIn China, and eventually form a new natural heart valve.

Xeltis

XeltisXeltis AG is a clinical-stage medical device company developing the most advanced polymer-based cardiovascular therapeutic repair devices.XeltisThe repair devices include those used for coronary artery bypass grafting surgery and hemodialysis vascular access, heart valves, and small-diameter blood vessels.

XeltisIt was formed by the merger of two enterprises incubated by Dutch/Swiss universities and currently operates in the Netherlands and the United States.